The medical technology company Aesculap has increased its sales in the first nine months of this year by 6.3 percent to EUR 1.05 billion.
A downside, however, was that they had lower sales in Europe, where 65 percent of total revenues were generated. As health expenditure in many countries are linked to government spending, the euro-debt crisis has now also hit the medical device industry. An increase in revenues for the subsidiary of B. Braun Melsungen AG was recorded, however, in the U.S., Chinese and Russian markets.
For the full year Aesculap expects a revenue increase of 6.5 percent. „We are aiming at 1.4 billion“, said CEO Hanns-Peter Knaebel. The original forecast is for a more than proportional increase in earnings, but the profit is higher than the previous year’s figure of EUR 269 million.
[ilink url=“https://www.bibliomed.de/news/-/content/detail/779786″] Link zur Quelle (Bibliomed)[/ilink]